Journals / Turkish Journal of Pediatrics / 2016 / Cilt: 58 - Sayı: 6

Low pertussis antibody levels in maternal and umbilical cord blood samples in Turkey

Pages
573–578
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These data support the need for pertussis vaccination during pregnancy to prevent infant infection in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pertussis continues to cause significant mortality and morbidity in many countries despite high vaccine coverage, especially among young infants.
📊
Key Findings & Data:Antibody titers to pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) were measured by in-house enzyme linked immunosorbent assay (ELISA) in 251 paired maternal delivery and cord blood samples.
💡
Conclusion & Impact:These data support the need for pertussis vaccination during pregnancy to prevent infant infection in Turkey.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Pertussis continues to cause significant mortality and morbidity in many countries despite high vaccine coverage, especially among young infants. The aim of the study was to determine pertussis antibody levels in paired maternal and cord blood samples, to evaluate the placental transfer of these antibodies, and to assess whether newborn infants have adequate antibody levels against pertussis. Antibody titers to pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) were measured by in-house enzyme linked immunosorbent assay (ELISA) in 251 paired maternal delivery and cord blood samples. Geometric mean concentrations (GMCs) of pertussis antibodies and cord:maternal GMC ratios were calculated. GMCs of maternal anti-PT and anti-FHA antibodies at delivery were 4.12 and 9.89 EU/ml, respectively. Cord GMCs were 133% and 131% of maternal delivery values for PT and FHA, respectively; demonstrating effective placental transfer. However, cord pertussis antibodies were at a low concentration; 5.49 EU/ml for PT and 12.73 EU/ml for FHA. Only 34.6% of infants had protective anti-PT levels (≥10 EU/ml) at birth. Anti-pertussis antibody concentrations were extremely low in pregnant women in Turkey where childhood pertussis vaccination coverage has been high for a long time. Despite effective placental antibody transfer, umbilical cord pertussis antibody concentrations are similarly low. A majority of young infants are vulnerable to pertussis infection until the onset of primary vaccinations. These data support the need for pertussis vaccination during pregnancy to prevent infant infection in Turkey.

🔖

Cite This Article

TÜRKOĞLU, E., SÖNMEZ, C., ÖZER, F. E., ÇÖPLÜ, N., KURUGÖL, Z. (2016). Low pertussis antibody levels in maternal and umbilical cord blood samples in Turkey. Turkish Journal of Pediatrics, Cilt: 58 - Sayı: 6, 573–578. https://ajindex.com/articles/412246

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Subaiya S, Dumolard L, Lydon P, Gacic-Dobo M, Eggers R, Conklin L. Global Routine Vaccination Coverage, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 1252- 1255. Pertussis vaccines: WHO position paper, August 2015. Wkly. Epidemiol Rec 2015; 90: 433-460.
  2. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22: 628-634.
  3. Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015; 135: 1475-1482. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002; 35: 162-167.
  4. Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014; 133: e513-e519. Van Rie A, Wendelboe AM, Englund JA. Role of maternal antibodies in infants. Pediatr Infect Dis J 2005; 24 (5 Suppl): 62-65.
  5. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-1906.
  6. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-1916.
  7. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181:1010-1013.
  8. Miller JJ, Harold KF, Ryan ML, Silverberg RJ, Lew E. Immunization against pertussis during the first four months of life. Pediatrics 1949; 4: 468-478.
  9. Bigham M, Konrad S, Van Buynder P, et al. Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. Vaccine 2014; 32: 6493- 6498. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190: 335-340.
  10. Fallo A, Manonelles G, Hozbor D, et al. Pertussis seroprevalence in adults, post-partum women and umbilical cord blood. Arch Argent Pediatr 2014; 112: 315-322.
  11. Ercan TE, Sonmez C, Vural M, Erginoz E, Torunoğlu MA, Perk Y. Seroprevalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine 2013; 31: 4172-4176.
  12. Gonik B, Puder KS, Gonik N, Kruger M. Seropreva